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Abstract 
Personalized medicine and targeted therapy have been emerging fields of study for the 
remediation and inhibition of cancer. Personalized medicine in the treatment of cancer involves 
using genetic, immune, and proteomic profiling to provide therapeutic options as well as 
prognostic background for every patient and their tumor’s genetic mutations. Targeted therapies 
allow researchers and medical personnel alike to determine the appropriate treatment for a patient 
based on the molecular basis and mechanistic actions of a cancerous tumor. The overall 
significance of this study was to express how these treatments use biomarkers to pinpoint the 
location, and severity of the cancer, and to administer the right treatment. Early detection of tumor‐
specific biomarkers can allow the use of non‐invasive routine monitoring.  
The study aims to provide an elaborate explanation on the various biomarker classification 
and present the protocol on how they are sorted and validated to be a potential cancer biomarker 
used in clinical practice. Categorizing biomarkers relies on their characteristics. These classifiers 
will divide them into one of the following groups: general biomarkers, DNA biomarkers, and DNA 
tumor biomarker. The expressions of microRNA also play a role in the determination of cancer, 
as most of these clusters regulate the expression and transcriptional activity of various cancer cell 
lines. The expression of the ER receptors in mammalian cells classifies breast cancer into one of 
the following categories: triple negative, estrogen receptor (ER) negative, or (ER) positive. ER 
positive breast cancer patients can positively benefit from personalized medicine as these patients 
have to undergo specific hormonal therapy and supplementary adjuvant chemotherapy to eliminate 
the estrogen-induced proliferation of these mammalian cells. Drugs like tamoxifen function as 
antagonists to the ER receptor to inhibit the transcriptional activity of the ER receptors. Other 
cancer types such as colorectal cancer, and lung cancer may also benefit from such approaches.   
2
Mako: NSU Undergraduate Student Journal, Vol. 2020 [2020], Art. 1
https://nsuworks.nova.edu/mako/vol2020/iss2/1
 
   
 
The limitations of the study include the unique genomic profiling of each patient, 
challenges in validation and implementation of drug combinations, and the deployment of 
technologies for DNA sequencing.   
Keywords: cancer, biomarkers, personalized medicine, gene therapy, targeted therapy, 
DNA Biomarker, RNA expressions, ER, colorectal cancer, lung cancer, prostate cancer, leukemia, 
targeted treatment 
 
I. Introduction to Personalized Medicine, Biomarkers, and Targeted Treatment  
The release of the first draft of the Human Genome Project (Collins et al., 2002) has 
allowed scientists and researchers to make much progress in the field of clinical medicine through 
the discovery of multiple genes. Scientists believe that these genes contribute to the growth and 
progression of various human illnesses. The Human Genome Project aims to progress the 
development of personalized medicine, which is an emerging path in the field of healthcare 
(Collins et al., 2003). Personalized medicine is an evidence-based approach for treating patient 
health concerns (Chan & Ginsberg, 2011). This approach analyzes the molecular mechanisms 
involved in the progression and development of the disease to enhance existing health strategies 
or to develop novel preventive health care measures (Hua et al., 2018). Its goal is to individualize 
patient care while offering the maximum medical care possible to remediate, and ultimately inhibit, 
the development of disease. The emergence of personalized medicine has been a promising 
movement to provide a more effective treatment for progressive diseases. The standard treatments, 
that are currently available, are quite invasive and limited (Chan & Ginsberg, 2011). Diseases 
situated in an inaccessible body part, or diseases in more advanced stages, may render treatments, 
such as chemotherapy, as inadequate to inhibit the proliferation of the disease. “Typical current 
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intervention” dictates treatments and its detection, it is costly to treat with low reversibility 
probabilities (Chan & Ginsburg, 2011). Novel genome-based drug formulations targeting specific 
biomarkers are emerging alternatives to general treatments. This formulation can help researchers 
and clinicians identify the disease and its baseline risks, since diagnostic biomarkers are invariant 
during disease progression and permit diagnosis in its early stages, thus lowering the cost and risks 
for the patient (Jain, 2002; Biomarkers Definitions Working Group, 2001).  
 
Figure 1. The application of genome-based technologies as personalized health care measures 
(taken from Chan & Ginsburg, 2011) 
The developments in the field of genomics have allowed scientists and researchers to 
pinpoint specific molecular events which lead to a progressive disease like cancer. These 
molecular events in the human body are chromosomal rearrangements, gene amplifications, and 
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other DNA mutations (Leary et al., 2010). These alterations at the genomic level are avoidable by 
the formulation of novel anti-cancer drugs, and the implementation of tailor-fitted adjuvant therapy 
to locate the prominent gene expression signatures created by a specific disease. Gene expression 
signatures can serve as biomarkers, which are biological molecules that function as indicators of 
body responses (Guo et al., 2016). Biomarkers are biological substances that are measured in the 
body and may affect the prediction and interpretation of any sickness outcomes (Ganesalingam & 
Bowser, 2010). 
II. Overview of Various Cancer Related Biomarkers 
A. Categories of Biomarkers 
 Biomarkers are useful in personalized medicine by providing better prognostic and 
predictive markers in comparison to the typical intervention processes (Hamburg & Collins, 2010). 
This advantage makes it easier for clinicians to provide a better treatment plan for patients. 
Biomarkers are classified into three distinct classifications: DNA biomarkers, DNA tumor 
biomarkers, and general biomarkers (Kamel et al., 2017). The discovery of new prognostic and 
predictive biomarkers drives the paradigm for the exploitation of genomic-based technologies in 
personalized medicine. Biomarkers are important for monitoring drug responses and deciding 
which patients will effectively respond to treatments. (Jariyal et al., 2020). 
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Figure 2. The paradigm for the exploitation of genomic-based technologies in personalized 
medicine (taken from Kamel et al., 2017). 
 
A.1. DNA Biomarkers 
The genetic information coded in the DNA should be stable since the DNA directs the 
protein synthesis needed for a proper cellular structure and function. DNA biomarkers are small, 
but distinct, sequence level variations of DNA, which include base pair insertions, deletions, single 
nucleotide polymorphisms (SNPs) and short tandem repeats (STRs) (Kamel et al., 2017). SNPs 
are a very common type of DNA biomarker due to the availability of high-throughput sequencing 
technologies and biological facilities. In addition, SNPs are diallelic in most applications yielding 
three possible genotypic combinations, which are indicators of epigenetic changes comprised of 
histone modifications and DNA methylation. 
An important consideration about these biomarkers is their stability in comparison with 
DNA tumor and general biomarkers. Their stability enables the storing of samples for longer 
periods of time. In addition, DNA biomarkers are reproducible, which deems advantageous in both 
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prospective and retrospective studies. Furthermore, these biomarkers have simpler storage and 
handling protocols, which yields a lower cost compared to the other biomarker types. However, 
DNA biomarkers cannot be of use for therapy monitoring and pharmacodynamics since the 
alterations made during the initiation of the disease remain the same throughout the advancement 
and proliferation of the disease (Ganesalingam & Bowser, 2010).     
A.2. DNA Tumor Biomarkers 
 DNA tumor biomarkers, on the other hand, are rearrangement-associated biomarkers 
specific to a cancerous tumor. Such alterations are present in the early stages of tumor formation 
and continue throughout tumor development. These tumor-specific chromosomal alterations can 
be specific biomarkers for tumor detection, since they are unique in cancerous cells and are absent 
in normal and healthy cells. Examples of these recurrent somatic alterations in hematopoietic 
malignancies usually include the following oncogenic genes: BCR-ABL fusion oncogene, T cell 
receptor genes, retinoic acid receptor α genes, and immunoglobulin genes (Leary et al., 2010).  
  
A.3. Predictive Biomarkers 
 Predictive biomarkers provide data about the possible and expected responses to a certain 
therapy. The biomarkers can provide a plan for a specific treatment. Predictive biomarkers are an 
anticipation of possible responses the body of the patient will have to the given treatment and how 
they can affect or improve it. These biomarkers guide the customized treatment plan for patients 
while getting more information about the malignancy and behavior of the tumor in analysis. 
Predictive biomarkers are sometimes shared between various tumor types. These predictive 
biomarkers might be of use in dose determination and selection studies as well as in response 
measurements of new biological agents. Examples of highly studied DNA biomarkers are the 
7
Asad and Schmitt Lavin: Personalized Medicine: The Use of Biomarkers and Molecularly Targ
Published by NSUWorks, 2020
 
   
 
mutations in gene protein encoders responsible for DNA damage repair. Oncogenes such as the 
breast cancer gene 1 (BRCA1), and the breast cancer gene 2 (BRCA2) can increase the risk of 
patients for breast cancer. Some common predictive biomarkers for selected cancers are 
summarized in Table 1.  
 
Table 1. Summary of predictive biomarkers for selected cancers (taken from Kamel et al., 2017).  
Cancer Biomarker Clinical utility and significance 
Breast 
cancer  
PR High PR expression predicting beneficial response to tamoxifen 
therapy 
 ER High Cellular ER expression predicting benefit from tamoxifen-
based chemotherapy in node-negative patients 
 BRCA1 High BRCA1 expression predicting response to chemotherapy 
 HER2 Overexpression of HER2 predicting response to treatment with 
trastuzumab 
 AKT 
kinase 
isoform 
Akt kinase isoforms and activity predicting response to 
trastuzumab-based therapy in HER2-positive metastatic cancer 
patients 
Colorectal 
cancer 
LOH at 
18q 
Predicting benefit from 5-FU based adjuvant chemotherapy  
 EGFR1 EGFR1 amplification predicting response to anti-EGFR1 antibody 
therapy 
 KRAS KRAS mutation negatively predicting benefit from EGFR-targeted 
therapy 
Non-small 
cell lung 
cancer 
BRCA1 High BRCA1 expression predicting resistance to chemotherapy 
 TP53 High TP53 expression predicting sensitivity to cisplatin; TP53 
mutations predicting resistance to cisplatin 
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 KRAS KRAS mutation predicting lack of response to adjuvant 
chemotherapy in early disease and resistance to treatment with 
EGFR-targeted or TKI in advanced disease 
 
III. Discussion  
A. The Role of MicroRNA Expressions in Cancer 
  Molecular biology provides the technology to develop and identify biomarkers, which are 
used in therapies such as RNA/DNA microarray tests that help to rationalize and personalize 
treatment plans (Crommelin, 2011). MicroRNA (miRNA) expression is a gene expression which 
has received much attention from researchers not because of its great advancement in scientific 
knowledge, but because they can be adjusted and used in many types of cancer as they are a gene 
expression that has a direct relation and interaction with the tumor causing the cancer (Mathe et 
al., 2017). MicroRNAs are fragments of small non-coding RNA that work to regulate gene 
expression at translational or post-transcriptional levels. MicroRNAs have important interactions 
with specific oncogenes in various types of cancers. For example, the development of a lymphoma 
is induced by miR-17, miR-20, and miR-92 microRNA clusters (Mathe et al., 2017). In addition, 
the overexpression of miR-106a is linked with the downregulation of RB1, a tumor suppressor, in 
lung, gastric, and prostate cancers (Kamel et al., 2017). MicroRNA’s regulate the expression of 
both the ERα and ERβ receptors. The expression, transcriptional activity, proliferative action of 
ERα, and the tumor-suppressor properties of ERβ affect the carcinogenic activity of estrogen that 
usually develops into breast cancer. In ERα-negative cancer cells, the expression of the miRNA-
206 increases, which targets the ERα mRNA 3’-untranslated regions (3’-UTR) inhibiting its 
expression. The microRNA, miR-27a, also inhibits ERα transcription by targeting the repressor of 
a specificity protein, ZBTB10, which regulates ERα expression (Mathe et al., 2015).    
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B. Targeted Gene Therapies for Cancer  
 B.1. Breast Cancer 
 Breast cancer is classified into four distinct classes based on the profiling of its gene 
expressions defined by a class of known molecular biomarkers (Sommer, 2001). The classification 
is summarized in Table 2. Breast cancer is the resulting of carcinogenic activity of estrogen (i.e., 
estrone, estradiol, and estriol) induced by the proliferative action of ERα through transcription, 
and by the tumor-suppressor properties of ERβ (Guiu et al., 2009; Perou et al., 2009; Sotiriou & 
Pusztai, 2009). One of the biological effects of estrogen is the mediation of both the binding and 
activation of the ERα and ERβ receptors. The ERα and ERβ receptors are classified under the 
superfamily of nuclear receptor transcription factors, which are classified by its DNA- and ligand-
binding domains (Duong et al., 2006).  
 
Table 2. Types of breast cancer based on gene expression profiling (taken from Kamel et al., 
2017).   
Classification Classification 
Luminal-A  Estrogen receptor positive, low histological grade 
Luminal-B Estrogen receptor positive, high histological grade 
Basal-Like Estrogen receptor negative, progesterone receptor negative, and human 
epidermal growth factor receptor 2 (HER2) negative 
HER2-Like HER-2 positive and overexpresses erb B-2 
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 Both Luminal-A and Luminal-B cancer show to have an increased expression and 
elevated levels of genetic biomarkers like those found in the normal breast myoepithelial cells (i.e., 
luminal cytokeratin). The proliferation of mammary cells induced by estrogen resulting to 
overexpression, disruption of cell cycle, and cell apoptosis is what characterizes ER-positive breast 
cancers. ER-positive breast cancers comprise around 80% of the total breast cancer cases. 
Hormonal therapy helps patients to inhibit the proliferation of cancer cells. 
 Breast cancer falls into classification of one of five molecular classes. 1, and 2 are luminal 
A and luminal B (hormone receptor positive). 3 is HER2-positive, a human epidermal growth 
factor receptor-2. Category 4 is basal-like and normal-like based on microarray and gene 
expression profiling and 5 claudin-low, triple-negative breast cancer, which includes medullary 
and metaplastic differentiation (Jeibouei et al., 2019). 
 
 
Figure 3. The estrogen-positive and estrogen-negative breast cancer  
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(taken from the National Cancer Institute, 2020).  
 
 An example of a drug administered under endocrine therapy for this type of cancer 
includes tamoxifen, a selective estrogen receptor modulator, which functions as an antagonist to 
inhibit the transcriptional activity of the ER receptors (American Cancer Society, 2020). 
Tamoxifen, a drug commonly used for hormone-positive breast cancer, blocks estrogen attachment 
to the ER receptors that dampen, or ultimate stop the cancer cell growth (National Cancer Institute, 
2020; Sneha & Doss, 2016).  
 
Figure 4. Chemical structure of tamoxifen. (Taken from Valny et al., 2016) 
 The basal-type cancers, on the other hand, do not overexpress the above-mentioned genes, 
but they correlate with other biomarkers like cytokeratin 5, epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), insulin growth factor (IGF)receptors. Statistics show that most 
breast cancers induced by BRCA1 mutations were of basal-like cancer classification (Kamel et al., 
2017).  
 The ligand-induced activation of the ER receptor starts with the binding of the agonists 
to the ER complex which induces a series of conformational changes in the receptor leading to the 
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dissociation of the chaperone protein, the heat shock protein 90 (hsp90), and the dimerization of 
the ER complex. The co-activator complex then binds to the dimerized receptor, which allows it 
to interact with the target DNA sequence. Then, the basal transcription factors interact with the 
attached co-activator complex which stimulates the acetylation of histones and the initiation of the 
transcription of the target gene. Histone modification reactions prior to transcription are necessary 
to transform the tightly coiled chromatin into a loose, and transcriptionally active structure. In 
addition, histone acetylation is an essential part of the ER activation process as histone deacetylase 
(HDAC) inhibitors can restore the transcriptional activity of the ERα receptor in ERα-negative 
breast cancer cells. In addition, HDAC inhibitors, as well as various available demethylating 
agents, serve as an effective treatment for ERα-negative breast cancer patients to induce the 
expression of the ERα receptor (Ogryzko et al., 1996). The entire transcription process of the ERα 
gene generates a 4.3 kb long mRNA sequence, which contains the 3’-UTR. This untranslated 
region contains various regulatory elements that may direct mRNA destabilization (Sommer, 
2001).      
 The antagonist-induced inhibition of the ER receptor, on the other hand, starts with the 
binding of the antagonist to the ER complex leading to the conformational changes distinct to those 
found in agonist binding, the dissociation of the hsp90 protein, and the dimerization of the ER 
complex (Sommer, 2001). The co-suppressor complex then binds to the dimerized receptor, which 
allows it to interact with the target DNA sequence. However, DNA binding does not recruit all the 
basal transcription factors leading to the inhibition of the transcription process (Sommer, 2001). 
Lastly, the co-suppressor complex deacetylates the histones through the action of HDAC, which 
prohibits the binding of the transcription factors into the tightly wrapped DNA around the histone 
cores (Sommer, 2001).   
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Figure 5. A simplified model of the agonist-induced stimulation and antagonist-induced 
inhibition of the ER-regulated gene transcription (Taken from Sommer, 2001).  
 
 B.2. Colorectal Cancer  
 Up to this date, there is a scarcity in information about the molecular alterations and gene 
translocations associated with colorectal cancer. Studies have shown that the progression of this 
type of cancer involves mutations of the genes that encode the Kirsten rat sarcoma (KRAS) viral 
oncogene, adenomatous polyposis coli (APC) protein, and the P53 or TP53 tumor protein. In 
addition, gene expression profiling studies have shown that the 23-gene signature can be a potential 
predictor for the recurrence of colorectal cancer amongst patients. These findings may help future 
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researchers in formulating appropriate gene therapies for colorectal cancer patients (Kamel et al., 
2017). 
 
 B.3. Prostate Cancer 
 Prostate cancer is one of the leading causes of mortality in men. Even if treatment seems 
to cure the cancer in its early stages, up to 50% of patients regress after initial therapy (Kafka et 
al., 2020). Studies show that the initiation and proliferation of prostate cancer cells catalyze from 
the deletion of the phosphatase and tensin homolog on chromosome 10 (PTEN), which is an 
essential gene responsible for tumor suppression. The translocation of the genes that encode the 
E-twenty-six specific related gene (ERG) and the serine 2 (TMPRSS2) transmembrane protease 
also contributes to the advancement of prostate cancer (Kamel et al., 2017). 
 
 B.4. Lung Cancer 
 In lung cancer there is a 5-gene and 12-gene signature gene expression pattern that 
correlates with the recurrence of lung cancer among patients after treatment. The 12-gene signature 
is used to classify patients according to susceptibility to adjuvant chemotherapy (Kamel et al., 
2017). A variety of lung cancer biomarkers help to dictate therapy, such as targeting tumor growth 
by specific drug therapies (EGFR, ALK, ROS1, HER2, BRAF/MEK, MET, and RET mutation 
and aberrancies) (Sears et al., 2020) 
 
C. Targeted Drug Therapy and Specific Gene Targets: HER2 and EGFR genes 
 The aim of personalized medicine and targeted drug therapy is to provide a customized 
treatment plan for patients according to the molecular profiles and signature expression of tumor 
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tissues. Trastuzumab is a monoclonal antibody used as an adjuvant therapy for HER2-positive 
metastatic breast cancer patients (Hurvitz et al., 2013). It induces the downregulation of the HER2 
gene which is overexpressed in the early stages of the breast cancer. It also acts as a tyrosine kinase 
inhibitor in colorectal cancer and chronic myelogenous leukemia patients. In addition, trastuzumab 
inhibits the expression of the EGFR gene in EGFR mutation induced lung cancer. Lapatinib, on 
the other hand, is a drug that targets the HER2 and possesses a high affinity for the EGFR gene, 
specifically in the EGFR1 intracellular domains (Hurvitz et al., 2013; Kamel et al., 2017). It is also 
a tyrosine kinase inhibitor that, in conjunction with trastuzumab, remediates the progression of the 
invasive HER2-positive breast cancer. Other drugs and targeted therapies for selected types of 
cancer are summarized in Table 3, Figure 3, and Appendices A-C. 
 
Table 3. Summary of targeted therapies for selected types of cancers (taken from Kamel et al., 
2017). 
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Figure 6. Body map of the available markers and targeted therapies for cancer  
(taken from Kamel et al., 2017).  
 Amidst all the advantages presented on personalized medicine, this emerging field also has 
a list of limitations which can be source of future potential research to further the knowledge on 
cancer and how it can be treated. Such limitations include the unique genomic profiling of each 
patient. These small mutations in the genomic sequence can drive the development of medication 
in cohorts based on the frequency of these genomic alterations. In addition, challenges in validation 
and implementation of drug combinations, as well the deployment of technologies for DNA 
sequencing can limit the scope of the study.  Further research needs to probe on the development 
of advance genomic algorithms which can implement high accurate and reliable software that can 
be used for personalized medicine.  
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IV. Conclusion 
Personalized medicine is a futuristic and potentially idealistic system to help every patient 
seek for and obtain urgent, specialized attention. It could change the approach to medicine, as well 
as the attention given to a patient with cancer, specifically attending to the issues the person is 
presenting and the cancerous cells the patient has in the respective body part. Biomarkers in the 
therapy for cancer patients could be a helpful tool to provide an on-time prognosis and treatment 
of the disease. It is also a futuristic plan that cancer patients should have the option to consider. 
Targeted therapy could also be a transformative change in medical attention, as the use of 
biomarkers in this therapy can identify the specific type of therapy the patient needs.  
 
V. Appendix:  
A. Drug & Gene Table 
This table covers 38 drugs undergoing study as gene treatment for 5 different cancers: 
Breast cancer, colorectal cancer, leukemia, non-small cell lung cancer, and prostate cancer. 
These drugs for targeted gene therapy were chosen from the National Cancer Institute, 
2020.  
With these 38 drugs, 17 genes are being targeted for treatment to solve the issue within the 
gene, causing cancer. They are classified into 13 different types of molecules. To determine 
which drug would be used for treatment, it should first be determined which gene has gone 
wrong. From there, a drug that treats the issue of that gene can be decided on. 
B.  Animated Flowcharts 
These flowcharts are simple visual depictions of the drug & gene table spreadsheet located 
in Appendix A. Each section is separated by cancer type, further branching into the 
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applicable treatments. Drugs that share a common gene target are grouped together. The 
flowchart gives more detail about each oncogene: the type of molecule, which chromosome 
it is located on, the issue leading to cancer, and the gene’s function. 
C. Illustrations 
These illustrations explain targeted cancer treatments in a simplified way.  
Image 1: The switching of pre-cancerous proto-oncogenes into cancerous Oncogenes.  
This image shows genes forcibly turning on the cancer switch, due to the function of 
oncogenes.  
Image 2: Ways that the expression of some key oncogenes can be lessened. 
This image conveys a group of oncogenes seeking therapy to treat their abnormalities.  
Image 3: Learning about different drugs for treating specific oncogenes.  
This illustration describes the specific treatment for the abnormality in the gene, mTOR,  
and prescribes specialized drug treatment. 
Image 4: Diagnosing a specific gene abnormality and prescribing treatment. 
In this image, Gleevec is prescribed to treat the abnormality in the gene, BCR-ABL1.  
The abnormality can lead to Leukemia, and Gleevec treats it by inhibiting protein kinase. 
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